Briakinumab - PubMed (original) (raw)
Review
Briakinumab
Xinaida Taligare Lima et al. Expert Opin Biol Ther. 2009 Aug.
Abstract
Background: Psoriasis is a chronic, autoimmune, T-cell mediated, inflammatory disease. An improved understanding of the pathogenesis of the autoimmune response has led to the development of targeted biologic therapies. Briakinumab is a human monocolonal antibody that blocks the activity of the cytokines IL-12 and IL-23. Immune dysregulation has been implicated in multiple inflammatory disorders and briakinumab has been investigated for the treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Objectives: This review focuses on briakinumab and its use in chronic plaque-type psoriasis.
Methods: A literature review was performed, searching Medline and the clinicaltrials.gov database for all articles with the keywords ABT-874, IL-12/IL-23 and psoriasis.
Conclusions: Although limited by small sample sizes, length of follow-up, and a lack of direct comparisons with other psoriasis treatments, initial data regarding the safety and efficacy of briakinumab for the treatment of psoriasis is promising. Ongoing Phase III trials may provide additional information regarding the relative efficacy and safety of briakinumab.
Similar articles
- Briakinumab for the treatment of plaque psoriasis.
Traczewski P, Rudnicka L. Traczewski P, et al. BioDrugs. 2012 Feb 1;26(1):9-20. doi: 10.2165/11595940-000000000-00000. BioDrugs. 2012. PMID: 22077474 Review. - Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M, Alwawi E, Gordon KB. Gandhi M, et al. Semin Cutan Med Surg. 2010 Mar;29(1):48-52. doi: 10.1016/j.sder.2010.02.001. Semin Cutan Med Surg. 2010. PMID: 20430307 Review. - Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR. Mudigonda P, et al. Dermatol Online J. 2012 Oct 15;18(10):1. Dermatol Online J. 2012. PMID: 23122008 Review. - Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
Griffiths CE, Girolomoni G. Griffiths CE, et al. J Eur Acad Dermatol Venereol. 2012 Aug;26 Suppl 5:2-8. doi: 10.1111/j.1468-3083.2012.04604.x. J Eur Acad Dermatol Venereol. 2012. PMID: 22758911 Review. - Prospective new biologic therapies for psoriasis and psoriatic arthritis.
Mortel MR, Emer J. Mortel MR, et al. J Drugs Dermatol. 2010 Aug;9(8):947-58. J Drugs Dermatol. 2010. PMID: 20684145 Review.
Cited by
- The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options.
Patel HA, Revankar RR, Pedroza ST, Graham S, Feldman SR. Patel HA, et al. Int J Mol Sci. 2023 Aug 1;24(15):12310. doi: 10.3390/ijms241512310. Int J Mol Sci. 2023. PMID: 37569685 Free PMC article. Review. - Assessing developability early in the discovery process for novel biologics.
Fernández-Quintero ML, Ljungars A, Waibl F, Greiff V, Andersen JT, Gjølberg TT, Jenkins TP, Voldborg BG, Grav LM, Kumar S, Georges G, Kettenberger H, Liedl KR, Tessier PM, McCafferty J, Laustsen AH. Fernández-Quintero ML, et al. MAbs. 2023 Jan-Dec;15(1):2171248. doi: 10.1080/19420862.2023.2171248. MAbs. 2023. PMID: 36823021 Free PMC article. Review. - Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life.
Gjølberg TT, Frick R, Mester S, Foss S, Grevys A, Høydahl LS, Jørstad ØK, Schlothauer T, Sandlie I, Moe MC, Andersen JT. Gjølberg TT, et al. Commun Biol. 2022 Aug 18;5(1):832. doi: 10.1038/s42003-022-03787-x. Commun Biol. 2022. PMID: 35982144 Free PMC article. - Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life.
Grevys A, Frick R, Mester S, Flem-Karlsen K, Nilsen J, Foss S, Sand KMK, Emrich T, Fischer JAA, Greiff V, Sandlie I, Schlothauer T, Andersen JT. Grevys A, et al. iScience. 2022 Jan 10;25(2):103746. doi: 10.1016/j.isci.2022.103746. eCollection 2022 Feb 18. iScience. 2022. PMID: 35118359 Free PMC article. - Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis.
Sawarkar SP, Yadav V. Sawarkar SP, et al. Indian J Dermatol Venereol Leprol. 2021 May-Jun;87(3):333-340. doi: 10.25259/IJDVL_470_19. Indian J Dermatol Venereol Leprol. 2021. PMID: 33943062 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical